Photo from wikipedia
We thank our colleagues for the interest in our manuscript [1] on invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children. The letter addresses a… Click to show full abstract
We thank our colleagues for the interest in our manuscript [1] on invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children. The letter addresses a statement in the Expert opinion section referring to the 15-valent pneumococcal conjugate vaccine (PCV15) which in our colleagues’ opinion does not accurately reflect the performance of the vaccine, as it refers to an earlier formulation which has been since improved and approved for use in the US. We would like to point out the following:
Journal Title: Expert Review of Vaccines
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!